Otani Machiko, Rowley Jane, Grankov Viatcheslav, Kuchukhidze Giorgi, Bivol Stela
World Health Organization Regional Office for Europe, Copenhagen, Denmark.
Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes, World Health Organization, Geneva, Switzerland.
BMC Public Health. 2025 Apr 25;25(1):1545. doi: 10.1186/s12889-025-22630-6.
Sexually transmitted infections (STIs) continue to be a significant public health challenge and have an impact on sexual and reproductive health. European Union and European Economic Area (EU/EEA) countries report data annually on the number of cases of syphilis, gonorrhoea, chlamydia, and lymphogranuloma venereum (LGV) to the European Centre for Disease Prevention and Control. No similar system exists for the non-EU/EEA countries in the WHO European Region, and therefore, the sub-regional overview was unclear due to the limited data availability and inconsistency.
We conducted a survey among 24 WHO member states in the WHO European Region that did not belong to the EU/EEA as of June 2024. The survey collected data on STI surveillance systems and numbers of reported cases of syphilis, gonorrhoea, chlamydia and LGV from 2021 to 2023.
Twenty-one completed the survey, of which 19 (79%) agreed to publish their data. All 19 countries reported surveillance activities for syphilis, 18 for gonorrhoea and chlamydia, and 8 for LGV. The comprehensiveness and coverage of surveillance systems varied between countries and infections. Total cases reported increased from 13,553 to 17,113 (notification rate per 100,000 population 5.4 to 6.9) for syphilis and 12,001 to 13,067 (4.2 to 5.0) for gonorrhoea between 2021 and 2023, while chlamydia cases decreased from 32,556 to 27,802 (13.3 to 11.2). Only one to two LGV cases were reported per year. Various challenges were identified in antimicrobial-resistant gonorrhoea surveillance.
In non-EU/EEA countries, STI cases are likely to be underreported due to incomplete surveillance systems and other factors. Given the increase in the number of reported cases of syphilis and gonorrhoea between 2021 and 2023 and the significant public health consequences of untreated STIs, an accelerated joint effort to strengthen the surveillance systems of the non-EU/EEA countries is warranted to move towards ending epidemics of STIs in the WHO European Region by 2030.
性传播感染(STIs)仍然是一项重大的公共卫生挑战,对性健康和生殖健康产生影响。欧盟和欧洲经济区(EU/EEA)国家每年向欧洲疾病预防控制中心报告梅毒、淋病、衣原体和性病性淋巴肉芽肿(LGV)的病例数。世卫组织欧洲区域的非欧盟/欧洲经济区国家不存在类似的系统,因此,由于数据有限和不一致,次区域概况尚不清楚。
我们对截至2024年6月不属于欧盟/欧洲经济区的世卫组织欧洲区域的24个成员国进行了一项调查。该调查收集了2021年至2023年性传播感染监测系统以及梅毒、淋病、衣原体和LGV报告病例数的数据。
21个国家完成了调查,其中19个国家(79%)同意公布其数据。所有19个国家都报告了梅毒监测活动,18个国家报告了淋病和衣原体监测活动,8个国家报告了LGV监测活动。各国之间以及不同感染的监测系统的全面性和覆盖范围各不相同。2021年至2023年期间,梅毒报告的总病例数从13553例增加到17113例(每10万人口的报告率从5.4增加到6.9),淋病从12001例增加到13067例(从4.2增加到5.0),而衣原体病例从32556例减少到27802例(从13.3减少到11.2)。每年仅报告一至两例LGV病例。在耐抗菌药物淋病监测中发现了各种挑战。
在非欧盟/欧洲经济区国家,由于监测系统不完善和其他因素,性传播感染病例可能报告不足。鉴于2021年至2023年期间梅毒和淋病报告病例数有所增加,以及未经治疗的性传播感染对公共卫生造成的重大后果,有必要加快共同努力,加强非欧盟/欧洲经济区国家的监测系统,以便到2030年在世卫组织欧洲区域消除性传播感染流行。